Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,501–5,600 of 15,747
Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan
Furuse, Y. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05025 · Cited by 17
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children
Chow, E. J., & Englund, J. A. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.005 · Cited by 28
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Liang, H., Wu, Y., Yau, V., Yin, H.-X., Lowe, S., Bentley, R., Ahmed, M. A., Zhao, W., & Sun, C. (2022) · Vaccines · doi:10.3390/vaccines10091538 · Cited by 18
“tions, mainly including short-term, mild to moderate pain at the injection site, fatigue, and headache [77].”
BackgroundInfluentialPlatelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 Vaccination
Klug, M., Lazareva, O., Kirmes, K., Rosenbaum, M., Lukas, M., Weidlich, S., Spinner, C. D., von Scheidt, M., Gosetti, R., Baumbach, J., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1733934 · Cited by 16
A community effort in SARS‐CoV‐2 drug discovery
Schimunek, J., Seidl, P., Elez, K., Hempel, T., Le, T., Noé, F., Olsson, S., Raich, L., Winter, R., Gökcan, H., et al. (2023) · Molecular Informatics · doi:10.1002/minf.202300262 · Cited by 18
Reopening California: Seeking robust, non-dominated COVID-19 exit strategies
de Lima, P. N., Lempert, R. J., Vardavas, R., Baker, L., Ringel, J., Rutter, C. M., Ozik, J., & Collier, N. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259166 · Cited by 17
“While vaccine efficacy to prevent disease has been established, vaccine efficacy to prevent infection is unknown at the time of this writing [6, 46, 47].”
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 15
Zuily, S., Lefèvre, B., Sanchez, O., de Vendin, O. E., Ciancio, G. D., Arlet, J., Khider, L., Terriat, B., Greigert, H., Robert, C., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102031 · Cited by 16
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy
Iovino, L., Thur, L. A., Gnjatic, S., Chapuis, A. G., Milano, F., & Hill, J. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002392 · Cited by 19
Mass spectrometric based detection of protein nucleotidylation in the RNA polymerase of SARS-CoV-2
Conti, B. J., Leicht, A. S., Kirchdoerfer, R. N., & Sussman, M. R. (2021) · Communications Chemistry · doi:10.1038/s42004-021-00476-4 · Cited by 15
Azzam, S. H., Mukari, A., Hamed, M., & Kridin, K. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15251 · Cited by 16
Aparicio, B., Casares, N., Egea, J., Ruiz, M., Llópiz, D., Maestro, S., Olagüe, C., González‐Aseguinolaza, G., Smerdou, C., de Cerio, A. L.-D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1978823 · Cited by 17
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 17
Sugito, N., Heishima, K., & Akao, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.001 · Cited by 17
Mu, X., Cohen, C. A., Leung, D., Duque, J. S. R., Cheng, S. M. S., Chung, Y., Wong, H. H. W., Lee, A. M. T., Li, W. Y., Tam, I. Y. S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01282-7 · Cited by 16
“As one of the two most used vaccines worldwide, Pfizer-BioNTech-Fosun Pharma COVID-19 (BNT162b2) vaccine is a nucleoside-modified and lipid nanoparticle-formulated mRNA vaccine encoding the wild-type SARS-CoV-2 spike (S) glycoprotein,(4) which has demonstrated 95% efficacy in preventing COVID-19 after two doses in adu…”
BackgroundAppearance of anti-MDA5 antibody-positive dermatomyositis after COVID-19 vaccination
Sugimoto, T., Yorishima, A., Oka, N., Masuda, S., Nakamoto, N., Kidoguchi, G., Watanabe, H., Yoshida, Y., Mokuda, S., & Hirata, S. (2022) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxac064 · Cited by 17
Membrane Microvesicles as Potential Vaccine Candidates
Shkair, L., Garanina, E. E., Stott-Marshall, R. J., Foster, T. L., Rizvanov, A. A., & Khaiboullina, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031142 · Cited by 17
Krekeler, C., Reitnauer, L. E., Bacher, U., Khandanpour, C., Steger, L., Boeckel, G. R., Klosner, J., Tepasse, P., Kemper, M., Hennies, M. T., et al. (2022) · Cancers · doi:10.3390/cancers14225512 · Cited by 16
Reimagining drug nanocarriers: clinical realities and smarter strategies for targeted drug delivery
Baker, A. G., & Fruk, L. (2025) · Materials Horizons · doi:10.1039/d5mh00927h · Cited by 21
Goldin, S., Adler, L., Azuri, J., Mendel, L., Haviv, S., & Maimon, N. (2022) · Gerontology · doi:10.1159/000521899 · Cited by 17
Sobolik, J. S., Sajewski, E. T., Jaykus, L., Cooper, D. K., Lopman, B. A., Kraay, A. N. M., Ryan, P. B., & León, J. S. (2021) · Food Control · doi:10.1016/j.foodcont.2021.108632 · Cited by 19
Self-citationSelma‐Royo, M., Bäuerl, C., Tudela, D. M., Aguilar‐Camprubí, L., Pérez-Cano, F. J., Llorca, A. P., Lerín, C., Martínez‐Costa, C., & Collado, M. C. (2021) · medRxiv · doi:10.1101/2021.05.20.21257512 · Cited by 16
Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
Wisnewski, A. V., Redlich, C. A., Kamath, K., Abad, Q.-A., Smith, R., Fazen, L. E., Santiago, R., Liu, J., Luna, J. C., Martinez, B., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252849 · Cited by 16
“The first mRNA vaccines for COVID-19 have been shown to elicit antibodies with significant neutralizing capacity in vitro and protect against severe disease in vivo (3-6).”
BackgroundBell's palsy following COVID-19 vaccine administration in HIV+ patient
Mussatto, C. C., Sokol, J. A., & Alapati, N. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101259 · Cited by 15
Unexpected vaginal bleeding and COVID-19 vaccination in nonmenstruating women
Blix, K., Laake, I., Juvet, L. K., Robertson, A. H., Caspersen, I. H., Mjaaland, S., Skodvin, S. N., Magnus, P. M., Feiring, B., & Trogstad, L. (2023) · Science Advances · doi:10.1126/sciadv.adg1391 · Cited by 21
Abuhammad, S., Khabour, O. F., Alzoubi, K. H., Hamaideh, S. H., Alzoubi, B. A., Telfah, W. S., & El-zubi, F. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271625 · Cited by 18
Lv, J., Fan, Q., Zhang, Y., Zhou, X., Yu, P., Yu, X., Xin, C., Hong, J., & Cheng, Y. (2025) · Advanced Science · doi:10.1002/advs.202413006 · Cited by 20
Taucher, C., Lazarus, R., Dellago, H., Maurer, G., Weisova, P., Ramljak, I. C., Dubischar, K. L., Lilja, A., Eder-Lingelbach, S., Hochreiter, R., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.06.022 · Cited by 18
COVID-19 vaccination in people with multiple sclerosis, real-life experience
Alroughani, R., Al-Hashel, J., Abokalawa, F., AlMojel, M., & Ahmed, S. F. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107374 · Cited by 17
Kirkpatrick, J. N., Swaminathan, M., Adedipe, A. A., Garcia-Sayan, E. D., Hung, J., Kelly, N., Kort, S., Nagueh, S. F., Poh, K. K., Sarwal, A., et al. (2023) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2023.08.020 · Cited by 15
Hung, K.-F., Hung, C., Hong, C., Chen, S., Sun, Y.-C., Wen, J.-W., Kuo, C., Ko, C., & Cheng, C. (2021) · Micromachines · doi:10.3390/mi12030321 · Cited by 17
Dursun, A. D., Sarıçam, E., Sarıyıldız, G. T., İşcanlı, M. D., & Cantekin, Ö. F. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s347977 · Cited by 18
“However, the BioNTech mRNA vaccine results have been published, but do not present data on discontinuation after the first and second dose or adverse reaction data by gender.(28) In diagnosis, cardiac involvement should be questioned in the younger population with chest pain after vaccination.”
MethodSung, K., Chang, T.-E., Wang, Y., Lin, C., Chang, C., Hou, M., & Lu, C. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000682 · Cited by 17
Olayiwola, M. O., Alaje, A. I., Yunus, A. O., Adedokun, K. A., & Bashiru, K. A. (2024) · Results in Control and Optimization · doi:10.1016/j.rico.2024.100384 · Cited by 18
Denholm, J. T., Venkatesh, B., Davis, J. S., Bowen, A. C., Hammond, N. E., Jha, V., McPhee, G. M., McQuilten, Z., O'Sullivan, M. V. N., Paterson, D. L., et al. (2022) · Trials · doi:10.1186/s13063-022-06929-y · Cited by 18
“Background The development of COVID-19 vaccines with efficacy against both infection and severe disease is a welcome and remarkable development and key to pandemic control [1, 2].”
BackgroundDiscovering glycoRNA: Traditional and Non‐Canonical Approaches to Studying RNA Modifications
Caldwell, R. M., & Flynn, R. A. (2022) · Israel Journal of Chemistry · doi:10.1002/ijch.202200059 · Cited by 18
Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH
Tortellini, E., Zingaropoli, M. A., Mancarella, G., Marocco, R., Carraro, A., Jamhour, M., Barbato, C., Guardiani, M., Dominelli, F., Pasculli, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314988 · Cited by 17
Nicolaidou, V., Georgiou, R., Christofidou, M., Felekkis, K. N., Pieri, M., & Papaneophytou, C. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032957 · Cited by 23
“However, the initial clinical trials for these vaccines did not include pregnant and lactating women [4,5].”
BackgroundOrbital Inflammatory Pseudotumor following mRNA COVID-19 Vaccination
Gencoglu, A. Y., & Mangan, M. S. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2093757 · Cited by 16
“It activates the innate and adaptive responses against SARS-CoV-2 and exhibits 95% efficacy in preventing the disease.(3) Several immune-related ophthalmic complications, including uveitis,(4) corneal graft rejection,(5) optic neuritis,(6) peripheral ulcerative keratitis,(7) and Graves’(8) disease, have previously bee…”
BackgroundChristensen, I. E., Jyssum, I., Tveter, A. T., Sexton, J., Tran, T. T., Mjaaland, S., Kro, G. B., Kvien, T. K., Warren, D. J., Jahnsen, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02587-8 · Cited by 18
Ren, P., Mengjie, Y., Xiaogang, S., He, W., Danna, Z., Yuqun, Z., Juan, J., & Qiang, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.951096 · Cited by 18
“The latest clinical trials have demonstrated that they can effectively reduce morbidity and mortality and the incidence of adverse events in a healthy population (4, 5).”
BackgroundRisk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD
Cannatelli, R., Ferretti, F., Carmagnola, S., Bergna, I. M. B., Monico, M. C., Maconi, G., & Ardizzone, S. (2021) · Gut · doi:10.1136/gutjnl-2021-326237 · Cited by 16
Cheng, Q., Farbiak, L., Vaidya, A., Guerrero, E. D., Lee, E. E., Rose, E. K., Wang, X., Robinson, J. J., Lee, S. M., Wei, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313009120 · Cited by 20
Dolzhikova, I. V., Gushchin, V. А., Shcheblyakov, D. V., Tsybin, A. N., Shchetinin, A. M., Pochtovyi, A. A., Komissarov, A. B., Kleymenov, D. A., Kuznetsova, N. A., Ильдарович, Т. А., et al. (2021) · medRxiv · doi:10.1101/2021.10.08.21264715 · Cited by 18
Golombek, S., Doll, I., Kaufmann, L., Lescan, M., Schlensak, C., & Avci‐Adali, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126599 · Cited by 16
Pettigrew, Z. J., Kim, M. H., & Becker‐Dreps, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_12 · Cited by 18
Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development
Hwang, G.-R., Yuen, J. G., & Ju, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041624 · Cited by 15
Leukocytoclastic vasculitis after COVID ‐19 vaccination
Altun, E., & Kuzucular, E. (2021) · Dermatologic Therapy · doi:10.1111/dth.15279 · Cited by 16
“Common side effects include mild to moderate tenderness at the injection site, fever, fatigue, body ache, and headache.(2) Leukocytoclastic vasculitis (LCV), also known as hypersensitivity vasculitis, is the vasculitis of small vessels, which causes vascular damage and extravasation of erythrocytes with the accumulati…”
BackgroundSafdar, S., Ngonghala, C. N., & Gumel, A. B. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023009 · Cited by 18
Yonezawa, H., Ohmura, S., Ohkubo, Y., & Miyamoto, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0257-22 · Cited by 18
Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
Dix, C. H. K., McFadyen, J. D., Huang, A., Chunilal, S. D., Chen, V. M. Y., & Tran, H. A. (2022) · Internal Medicine Journal · doi:10.1111/imj.15783 · Cited by 16
Effective transcatheter intracoronary delivery of mRNA-lipid nanoparticles targeting the heart
Handa, K., Kawamura, M., Sasai, M., Matsuzaki, T., Harada, A., Fujimura, L., Whitehouse, J., Saito, S., Komukai, S., Kitamura, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113623 · Cited by 22
Chantasrisawad, N., Puthanakit, T., Tangsathapornpong, A., Techasaensiri, C., Phongsamart, W., Suwanpakdee, D., Jaru-Ampornpan, P., Sophonphan, J., Suntarattiwong, P., & Chotpitayasunondh, T. (2022) · Vaccines · doi:10.3390/vaccines10060871 · Cited by 16
“These rates of systemic reactogenicity reporting were only half of what had been reported from the pivotal trial of BNT162b2 among adolescents, aged 12–15 years (65–66%) [10], and adults (52–59%) [30].”
BackgroundResultWan, E. Y. F., Chui, C. S. L., Ng, V. W. S., Wang, Y., Yan, V. K. C., Lam, I. C. H., Fan, M., Lai, F. T. T., Chan, E. W., Li, X., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac460 · Cited by 17
Wong, C. K. H., Xiong, X., Lau, K. T. K., Chui, C. S. L., Lai, F. T. T., Li, X., Chan, E. W., Wan, E. Y. F., Au, I. C. H., Cowling, B. J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02321-4 · Cited by 17
“Exposure and follow‐up period In the present study, the recommended interval was defined as 21–28 days for BNT162b2 [34] and 14–28 days for CoronaVac [35, 36] (denoted as “recommended”), according to evidence based on the data from large-scale clinical trials and WHO recommendations.”
MethodThird COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Lake, D. F., Roeder, A. J., González‐Moa, M. J., Koehler, M. A., Kaleta, E. J., Jasbi, P., Vanderhoof, J., McKechnie, D., Forman, J., Edwards, B. A., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00151-2 · Cited by 16
Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review
Wang, C., Xiao, X., Feng, H., Hong, Z., Li, M., Tu, N., Li, X., Wang, K., & Bu, L. (2021) · Current Microbiology · doi:10.1007/s00284-021-02413-z · Cited by 17
Corona and Reproduction, or Why the Corona Vaccination Does Not Result in Infertility
Braun, A.-S., Feil, K., Reiser, E., Weiß, G., von Steuben, T., Pinggera, G., Köhn, F., & Tóth, B. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1750-9284 · Cited by 17
“As with the immune response elicited by vector vaccines, the use of mRNA vaccines also results in the production of specific antibodies [29,31,36].”
InfluentialAssociation between COVID-19 vaccination and menstruation: a state of the science review
Payne, L. A., Wise, L. A., Wesselink, A. K., Wang, S., Missmer, S. A., & Edelman, A. B. (2024) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2024-202274 · Cited by 19
Lai, F. T. T., Leung, M. T. Y., Chan, E. W. W., Huang, L., Lau, L. K. W., Peng, K., Leung, J. C. N., Fan, M., Chen, K., Lum, D. H., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.062 · Cited by 19
“However, successful infection control and risk mitigation strategies against Covid-19 [25] has led to a very low COVID-19 infection rate in Hong Kong ( 12,000 cases in a population of over seven million people as of July 2021).”
BackgroundResultInfluentialSzczepanek, J., Skorupa, M., Goroncy, A., Jarkiewicz‐Tretyn, J., Wypych, A., Sandomierz, D., Jarkiewicz-Tretyn, A., Dejewska, J., Ciechanowska, K., Pałgan, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10010099 · Cited by 20
Carletti, M., & Pancrazi, R. (2021) · Mathematics · doi:10.3390/math9020133 · Cited by 16
Montejano-Hervás, P., Gómez‐Pavón, J., Torres, O. T., Valverde-Moyar, M. V., Cruz, B. M., Carbonera, M. V., Fuentes-Irigoyen, R., González, P. T., González-Becerra, M., Sánchez, E. H., et al. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00959-6 · Cited by 16
“ADRs in our sample were less frequent than in the BNT162b2 clinical trial, however a higher number of severe adverse reactions were recorded [4].”
BackgroundResultTwo DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
Babuadze, G. G., Fausther‐Bovendo, H., Vega, M.-A. D. L., Lillie, B. N., Naghibosadat, M., Shahhosseini, N., Joyce, M., Saffran, H. A., Tyrrell, D. L., Falzarano, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00461-5 · Cited by 19
Williams, L. R., Ferguson, N. M., Donnelly, C. A., & Grassly, N. C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab914 · Cited by 15
Verleye, A., Wijtvliet, V. P. W. M., Abrams, S., Hellemans, R., Bougrea, R., Massart, A., Pipeleers, L., Wissing, K. M., Ariën, K. K., Winter, B. Y. D., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac174 · Cited by 17
“Both BNT162b2 and mRNA-1273 vaccines have each shown >90% efficacy in preventing COVID-19 illness in the general population [3, 4].”
BackgroundEarly safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis
Lotan, I., Hellmann, M. A., Friedman, Y., et al. (2022) · Neuromuscular Disorders · doi:10.1016/j.nmd.2022.01.013 · Cited by 16
Flynn, J. A., Weber, T., Cejas, P. J., Cox, K. S., Touch, S., Austin, L. A., Ou, Y., Citron, M. P., Luo, B., Gindy, M. E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.063 · Cited by 16
Sun, X., Zhao, X., Xu, Y., Yan, Y., Li, H., Wei, M., & He, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216794 · Cited by 20
Dynamic planning of a two-dose vaccination campaign with uncertain supplies
Calafiore, G. C., Parino, F., Zino, L., et al. (2022) · European Journal of Operational Research · doi:10.1016/j.ejor.2022.05.009 · Cited by 16
“…constraints, including the bounds n the interval between the administration of the first and the econd dose of the vaccine, and to formulate an objective funcion that accounts for the effectiveness of the partial immunization chieved with a single dose of the vaccine ( Polack, 2020; Voysey, 021 ).”
Costa, G. J., de Azevedo, C. R. A. S., Júnior, J. I. C., Bergmann, A. K., & Thuler, L. C. S. (2021) · Cancer · doi:10.1002/cncr.33832 · Cited by 14
Case report of acute encephalitis following the AstraZeneca COVID‐19 vaccine
Li, S., Chen, H., Liu, P., Shi, Z., Lin, Y., Tsai, C.-A., & Lin, S. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14372 · Cited by 15
Hartig, M., Stephens, C., Foster, A., Fontes, D. H., Kinzel, M., & García-Godoy, F. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211034164 · Cited by 19
“The most commonly reported vaccine side effects were fatigue, headache, and fever, which were quickly resolved.(67) We expect that Table 2.”
BackgroundMethodTaheri, S. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03471-x · Cited by 16
Leach, A., Ilca, F. T., Akbar, Z., Ferrari, M., Bentley, E. M., Mattiuzzo, G., Onuoha, S. C., Miller, A., Ali, H., & Rabbitts, T. H. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105147 · Cited by 16
Revolutionizing mRNA Vaccines Through Innovative Formulation and Delivery Strategies
Fatima, M., An, T., & Hong, K. (2025) · Biomolecules · doi:10.3390/biom15030359 · Cited by 22
Nealon, J., Mefsin, Y. M., McMenamin, M. E., Ainslie, K. E. C., & Cowling, B. J. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100451 · Cited by 21
“The first COVID-19 vaccine was approved for emergency use as a 2-dose schedule in December 2020 following randomized efficacy trials [1,2].”
MethodVanBlargan, L. A., Adams, L., Liu, Z.-M., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H.-Y., Case, J., Winkler, E. S., et al. (2021) · bioRxiv · doi:10.1101/2021.04.26.441501 · Cited by 15
Williams, N., Rosenblum, M., & Diaz, I. M. (2022) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/rssa.12915 · Cited by 23
“Governments and scientists around the globe have deployed an enormous amount of resources to combat the pandemic with remarkable success, such as the development in record time of highly effective vaccines to prevent disease (e.g., Baden et al., 2021; Polack et al., 2020).”
BackgroundNeuroleptic malignant syndrome following COVID-19 vaccination
Alfishawy, M., Bitar, Z. I., El-Gazzar, A., & Elzoueiry, M. M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.02.011 · Cited by 16
Xu, Y., Li, H., Kirui, B. K., Santosa, A., Gisslén, M., Leach, S., Wettermark, B., Vanfleteren, L. E. G. W., & Nyberg, F. (2022) · Vaccines · doi:10.3390/vaccines10122074 · Cited by 19
Nanobiotechnology-Enabled mRNA Stabilization
Xian, H., Zhang, Y., Yu, C., & Wang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020620 · Cited by 21
“Lipid nanoparticle (LNP) encapsulated-mRNA vaccines produced by Moderna (Spikevax®) [2] and Pfizer-BioNTech (Comirnaty®) [3] have helped millions of people against COVID-19.”
There is nothing exempt from the peril of mutation – The Omicron spike
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Anwer, M. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Bhatia, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112756 · Cited by 16
Malli, F., Lampropoulos, I. C., Papagiannis, D., Papathanasiou, I. V., Daniil, Z. D., & Gourgoulianis, K. I. (2022) · Vaccines · doi:10.3390/vaccines10020337 · Cited by 19
“The BNT162b2 vaccine (Pfizer BioNTech) has 95% efficacy against COVID-19 [5].”
BackgroundFava, V. M., Bourgey, M., Nawarathna, P. M., Orlova, M., Cassart, P., Vinh, D. C., Cheng, M. P., Bourque, G., Schurr, E., & Langlais, D. (2022) · Science Advances · doi:10.1126/sciadv.abm2510 · Cited by 17
Qin, S. X., Cheng, F. W. T., Kwok, W. C., Fung, L. W., Tian, T., Yiu, H. H. E., Bloom, C. I., McDonald, C. F., Cheung, C., Lai, F. T. T., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01364-7 · Cited by 17
“COVID-19 vaccine trials and real-world vaccine effectiveness (VE) studies have demonstrated high-level VE in the general population and older people [13, 14].”
Martinis, E., Ricci, C., Trevisan, C., Tomadini, G., & Tonon, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071969 · Cited by 20
“In particular, colorectal cancer is the third deadliest cancer in the world, accounting for an estimated 10% of total cancer-related deaths in 2020 [65].”
BackgroundClinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany
Joshi, K., Scholz, S. M., Maschio, M., Kohli, M. A., Lee, A., Fust, K., Ultsch, B., de Velde, N. V., & Beck, E. C. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2290388 · Cited by 16
“[16] Polack FP, Thomas SJ, Kitchin N, et al.”
Bermingham, C. R., Morgan, J., Ayoubkhani, D., Glickman, M., Islam, N., Sheikh, A., Sterne, J. A. C., Walker, A. S., & Nafilyan, V. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac157 · Cited by 14
Romero-Ibarguengoitia, M. E., González‐Cantú, A., Pozzi, C., Levi, R., Mollura, M., Sarti, R., Sanz‐Sánchez, M. Á., Rivera-Salinas, D., Hernández-Ruíz, Y. G., Armendariz-Vázquez, A. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894277 · Cited by 20
Wang, F., Zhang, M., Tian, M., Lou, J., Pan, L., Gao, X., Zhang, L., Lou, X., Zhu, L., Sheng, Y., et al. (2023) · Nano Research · doi:10.1007/s12274-023-6111-2 · Cited by 19
Zhou, X., Lu, H., Sang, M., Qiu, S., Yuan, Y., Wu, T., Chen, J., & Sun, Z. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2184754 · Cited by 18
Yakoubi, A., & Dhafer, C. E. B. (2022) · Plasmonics · doi:10.1007/s11468-022-01754-0 · Cited by 16
Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
Goyal, K., Goel, H., Baranwal, P., Tewary, A., Dixit, A., Pandey, A. K., Benjamin, M., Tanwar, P., Dey, A., Khan, F., et al. (2021) · Immuno · doi:10.3390/immuno1040032 · Cited by 18
Self-citationKapnick, S. M. (2022) · DNA and Cell Biology · doi:10.1089/dna.2021.0538 · Cited by 19
“In 2020, Pfizer-BioNTech and Moderna’s COVID-19 vaccines (BNT162B2 and mRNA1273, respectively) (Polack et al., 2020; Baden et al., 2021) were the first in the United States to receive Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA).”
BackgroundEmerging mRNA Technology for Liver Disease Therapy
Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 21
Association of Zip Code Vaccination Rate With COVID-19 Mortality in Chicago, Illinois
Zeng, S., Pelzer, K. M., Gibbons, R. D., Peek, M. E., & Parker, W. F. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14753 · Cited by 19
Delivery strategies of RNA therapeutics to leukocytes
Tarab‐Ravski, D., Stotsky‐Oterin, L., & Peer, D. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.016 · Cited by 17
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.